“I don’t think I’ve ever been as honoured and excited to be part of somebody’s mission as I am with Umoja.”
Veteran investor Dr. Robert Glassman discusses, among other things, why he decided to support Seattle-based immunotherapy company Umoja Biopharma’s transformative mission at this point in his career. The pre-clinical biotech company aims to revolutionize immunotherapy by retooling the patient’s immune system in vivo. Based on the pioneering work of Seattle Children’s Research Institute and Purdue University, Umoja’s approach leverages a range of synergistic innovative technologies to develop scalable, next-generation cancer immunotherapies.